Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines
- 1 June 2020
- journal article
- research article
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 4 (6) , 636-648
Abstract
The formulations of peptide-based antitumour vaccines being tested in clinical studies are generally associated with weak potency. Here, we show that pharmacokinetically tuning the responses of peptide vaccines by fusing the peptide epitopes to carrier proteins optimizes vaccine immunogenicity in mice. In particular, we show in immunized mice that the carrier protein transthyretin simultaneously optimizes three factors: efficient antigen uptake in draining lymphatics from the site of injection, protection of antigen payloads from proteolytic degradation and reduction of antigen presentation in uninflamed distal lymphoid organs. Optimizing these factors increases vaccine immunogenicity by up to 90-fold and maximizes the responses to viral antigens, tumour-associated antigens, oncofetal antigens and shared neoantigens. Protein–peptide epitope fusions represent a facile and generalizable strategy for enhancing the T-cell responses elicited by subunit vaccines.Keywords
Funding Information
- U.S. Department of Health & Human Services | National Institutes of Health (CA174795, CA174795)
This publication has 63 references indexed in Scilit:
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletionNature Medicine, 2013
- Nonviral delivery of self-amplifying RNA vaccinesProceedings of the National Academy of Sciences, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccinationProceedings of the National Academy of Sciences, 2011
- STING is a direct innate immune sensor of cyclic di-GMPNature, 2011
- In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particlesProceedings of the National Academy of Sciences, 2011
- Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responsesNature Materials, 2011
- Role of antigen persistence and dose for CD4+T-cell exhaustion and recoveryProceedings of the National Academy of Sciences, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 2008